Skip to main content
MS-DRG 839 · MDC 17 · Medical

MS-DRG 839: Chemotherapy with Acute Leukemia as Secondary Diagnosis without CC/MCC

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: IPPS Table 5 (MS-DRG weights): v44 FY2027 (final rule + CN3) (effective October 1, 2026); MS-DRG Definitions Manual: v44 (effective October 1, 2026). Next CMS release: FY2028 final rule (August 2027), effective October 1, 2027; an April 1 interim grouper update when CMS issues one for the IPPS Table 5 (MS-DRG weights); the FY2028 grouper, effective October 1, 2027 for the MS-DRG Definitions Manual.

Key facts for DRG 839

FY2027 relative weight
1.3782
Higher than 38% of all MS-DRGs
Change vs FY2026
-4.6%
FY2026 weight 1.4439
Geometric mean LOS
3.7 days
Arithmetic mean 4.2 days
MDC
17
Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
Severity level
without CC or MCC
National unadjusted operating payment
$9,437.91
Weight × $6,848.00 FY2027 standardized amount; capital adds $744.16
Transfer policy
Not a transfer DRG

TL;DR

MS-DRG 839 is a medical group in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), at its family's base level (without CC/MCC). CMS assigns it a FY2027 relative weight of 1.3782 with a geometric mean length of stay of 3.7 days and an arithmetic mean of 4.2. Its weight moved down 4.6% from FY2026 (1.4439). That weight is higher than 38% of all MS-DRGs. The v44 Definitions Manual assigns it through 3 chemotherapy (principal diagnosis) codes and 33 acute leukemia (secondary diagnosis) codes.

What changed from FY2026 to FY2027

CMS recalibrates every MS-DRG weight annually from the prior year's MedPAR claims. For DRG 839 the FY2027 relative weight is 1.3782 against 1.4439 in FY2026, a fall of 4.55%, which exceeds the 2% threshold worth re-checking in contract models.

FY2026 versus FY2027 payment factors for MS-DRG 839
MetricFY2026FY2027Change
Relative weight1.44391.3782-0.0657
Geometric mean LOS (days)4.03.7-0.3
Arithmetic mean LOS (days)4.54.2-0.3
Weights shown are the FY2027 final values after the 10% cap on year-over-year reductions where applicable.

CC and MCC family

DRG 839 stands alone: CMS does not split this base group by CC or MCC severity, so complication documentation does not move the assignment, although it still affects quality and risk-adjustment reporting.

National unadjusted payment for DRG 839

Multiplying the FY2027 relative weight (1.3782) by the national rates in IPPS Tables 1A and 1D, as corrected by notice CMS-1849-CN3, gives the base amounts below. This group has no CC/MCC sibling, so the amount does not change with secondary-diagnosis capture.

FY2027 national unadjusted IPPS payment for MS-DRG 839
ComponentNational rateDRG 839
Operating (labor and nonlabor share)$4,519.68 + $2,328.32 = $6,848.00$9,437.91
Capital (federal rate)$539.95$744.16
Operating plus capital$10,182.07
Assumes the full annual update (the hospital submitted quality data and is a meaningful EHR user). A hospital with a reduced update starts from $9,142.69 to $9,364.11 for the operating portion of this DRG.

These are national, unadjusted figures, not what a given hospital is paid. The labor share is multiplied by the hospital's wage index (Table 1A applies when the wage index is above 1.0 and Table 1B otherwise), and teaching (IME), disproportionate share (DSH), outlier, transfer and new-technology add-on rules then change the amount for each stay. Use the figures to compare groups and to size a documentation finding, not to forecast a remittance; the DRG payment calculator applies a hospital's own wage index and teaching and DSH factors to DRG 839.

Risk-adjusting diagnoses in this DRG

Appendix B of the v44 Definitions Manual lists 36 ICD-10-CM codes in the logic for DRG 839; 33 of them also map to a CMS-HCC V28 payment category, across 3 categories. The same documentation that supports the inpatient group feeds Medicare Advantage risk adjustment when the patient is an MA enrollee.

CMS-HCC V28 categories among the diagnoses in the logic for DRG 839
V28 HCCCategoryShared codesExamples
HCC 17Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic24C92.00, C92.01, C92.02
HCC 18Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid6C91.00, C91.01, C91.02
HCC 22Bladder, Colorectal, and Other Cancers3C92.40, C92.41, C92.42

Grouper logic (v44 Definitions Manual)

The manual's split table for Chemotherapy with Acute Leukemia As Secondary Diagnosis gives one row per combination of criteria and the MS-DRG it assigns. DRG 839 is the row where SDX Acute Leukemia is Yes, High Dose Chemo Agent is No, MCC is No, CC is No.

Split table for Chemotherapy with Acute Leukemia As Secondary Diagnosis
SDX Acute LeukemiaHigh Dose Chemo AgentMCCCCDRG
Yesnot checkedYesnot checked837
NoYesYesnot checked837
YesNoNoYes838
NoYesNonot checked838
YesNoNoNo839

Criteria stated in the manual

  • Without High Dose Chemo Agent

Chemotherapy (Principal Diagnosis): 3 ICD-10-CM codes in this DRG's assignment logic.

Chemotherapy (Principal Diagnosis) codes in the logic for DRG 839 (sample)
ICD-10-CM codeDescription
Z08Encounter for follow-up examination after completed treatment for malignant neoplasm
Z51.11Encounter for antineoplastic chemotherapy
Z51.12Encounter for antineoplastic immunotherapy

Acute Leukemia (Secondary Diagnosis): 33 ICD-10-CM codes in this DRG's assignment logic; the first 12 are shown.

Acute Leukemia (Secondary Diagnosis) codes in the logic for DRG 839 (sample)
ICD-10-CM codeDescription
C91.00Acute lymphoblastic leukemia not having achieved remission
C91.01Acute lymphoblastic leukemia, in remission
C91.02Acute lymphoblastic leukemia, in relapse
C92.00Acute myeloblastic leukemia, not having achieved remission
C92.01Acute myeloblastic leukemia, in remission
C92.02Acute myeloblastic leukemia, in relapse
C92.40Acute promyelocytic leukemia, not having achieved remission
C92.41Acute promyelocytic leukemia, in remission
C92.42Acute promyelocytic leukemia, in relapse
C92.50Acute myelomonocytic leukemia, not having achieved remission
C92.51Acute myelomonocytic leukemia, in remission
C92.52Acute myelomonocytic leukemia, in relapse

Code editor, HAC and CC/MCC exclusion notes for DRG 839

Table 6K part 3 excludes 33 secondary diagnoses from acting as a CC or MCC in MS-DRGs 837-839 (Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent), because they are part of the group's own logic: C91.00, C91.01, C91.02, C92.00 and others. On a stay in this family they do not move it to the with-CC or with-MCC member; the CC/MCC list shows every family with such exclusions.

The Definitions Manual lists the diagnosis and procedure codes that lead to DRG 839; these are the ones that are also on a Medicare Code Editor list and can draw that edit.

Medicare Code Editor v44 lists that include codes in the logic of DRG 839
MCE editListCodesExamples
Edit 9unacceptable principal diagnosis1Z08
Edit 11leukemia that makes autologous marrow or stem cell transfusion non-covered9C91.00, C92.00, C92.40

Documentation and denial exposure

As a medical DRG, assignment depends on the principal diagnosis sequenced from the attending's documentation; a secondary condition sequenced first, or a symptom code in place of the confirmed diagnosis, changes the MDC or the DRG. Because this family has no severity split, review risk concentrates on medical-necessity of the admission itself and on the two-midnight benchmark. Typical inpatient denial codes for this group: CARC 16 (claim lacks information needed to group the stay), CARC 50 (the admission or procedure is judged not medically necessary), CARC 97 (a service is bundled into the DRG payment).

For teams evaluating QuickIntell software

Evaluate a documentation and coding workflow for DRG 839

Explore QuickCode for qualified coder review and documentation clarification, or QuickScribe for clinician-reviewed visit documentation. Confirm inpatient scope, the supported grouper version and reviewer responsibilities during evaluation. This public reference is not a production grouper and does not determine a claim's reimbursement.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — DRG 839

What is MS-DRG 839?

MS-DRG 839 is "Chemotherapy with Acute Leukemia as Secondary Diagnosis without CC/MCC", a medical Medicare Severity Diagnosis-Related Group in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms). Medicare pays inpatient stays grouped here at the hospital's base rate multiplied by the DRG relative weight.

What is the FY2027 relative weight for DRG 839?

The FY2027 relative weight is 1.3782 (IPPS final rule Table 5, effective October 1, 2026). In FY2026 it was 1.4439, a change of -4.6%.

What is the Medicare base payment for MS-DRG 839?

$9,437.91 for operating costs plus $744.16 for capital, $10,182.07 together, at the FY2027 national rates: weight 1.3782 times the $6,848.00 operating standardized amount and the $539.95 capital rate (IPPS Tables 1A and 1D as corrected by CMS-1849-CN3). The hospital's wage index, IME, DSH, outlier and transfer adjustments change what a given stay is paid.

What is the average length of stay for DRG 839?

CMS reports a geometric mean length of stay of 3.7 days and an arithmetic mean of 4.2 days for FY2027. The geometric mean is used for transfer-payment calculations.

What documentation supports the severity level of DRG 839?

DRG 839 is the base-severity assignment: no secondary diagnosis on the CC or MCC lists was coded, or the only ones present are excluded for this principal diagnosis. Revenue-integrity review here looks for undercapture, meaning conditions treated during the stay (electrolyte disorders, specified anemia, acute blood loss, pressure injuries present on admission) that were never documented to the specificity the lists require. A compliant query to the attending, not a coder assumption, is the only way to move a stay to the CC or MCC sibling.

Which codes group to DRG 839?

The v44 Definitions Manual lists 3 chemotherapy (principal diagnosis) codes and 33 acute leukemia (secondary diagnosis) codes for this group. Examples from the chemotherapy (principal diagnosis) list, Z08 (Encounter for follow-up examination after completed treatment for malignant neoplasm); Z51.11 (Encounter for antineoplastic chemotherapy); and from the acute leukemia (secondary diagnosis) list, C91.00 (Acute lymphoblastic leukemia not having achieved remission); C91.01 (Acute lymphoblastic leukemia, in remission).

Is DRG 839 a post-acute transfer DRG?

No. DRG 839 is not on the FY2027 post-acute care transfer list, so the transfer per-diem policy does not apply to it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from the CMS IPPS FY2027 final rule (Table 5) and the v44 ICD-10 MS-DRG Definitions Manual. Relative weights are national factors; actual payment depends on each hospital's wage-adjusted base rate, add-ons, outliers and transfer adjustments. Nothing here is legal, clinical or billing advice; verify grouping against your encoder and the published CMS files.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.